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Abstract
The present study describes the clinical and immunological features of children with Hib vaccine failure, who were identiﬁed through
national surveillance between 1996 and 2001 in Europe, Israel and Australia. True vaccine failure was deﬁned as invasive Hib disease
occurring ‡2 weeks after one dose, given after the ﬁrst birthday, or ‡1 week after ‡2 doses, given at <1 year of age. Of the 423 cases
(representing 0.2 cases per 100 000 child-years at risk) reported, 330 (78%) had received three doses in the ﬁrst year of life and devel-
oped disease at a median age of 28 months. Of the remaining 93, 48 had received two doses in infancy, 34 had received four doses
including a booster, and 11 had received a single dose after 12 months of age. These children developed disease at a median age of 12,
33 and 71 months, respectively. In total, 47 out of 258 children (18%) with available information had an underlying medical problem
(including prematurity) and 53 out of 161 (33%) had immunoglobulin deﬁciency. Convalescent Hib antibody concentrations were above
the putative protective concentration of 1.0 mg/L in 147/194 (76%) children; low concentrations were associated with both the pres-
ence of an underlying medical problem and young age at the time of Hib disease. Almost all children who received an additional vaccine
dose developed antibodies at protective concentrations. Thus, Hib vaccine failure is rare, but can occur with any immunization schedule.
Children with Hib vaccine failure should have immunoglobulin and convalescent Hib antibody concentrations measured after infection
and receive additional vaccination, if required.
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Introduction
The Hib conjugate vaccine is highly effective in preventing
invasive Hib disease [1–4] and its introduction into national
immunization programmes has resulted in a dramatic reduc-
tion in the incidence of invasive Hib disease across all ages,
through both direct and indirect protection [5–11]. The
development of invasive Hib disease after immunization (i.e.
Hib vaccine failure) is rare and sometimes is associated with
an underlying medical problem. In a study conducted in the
UK, for example, 44% were found to have a clinical risk fac-
tor and/or immunoglobulin deﬁciency [12]. Earlier studies
involving children vaccinated at an older age also reported
immunoglobulin deﬁciency in 35–40% [13,14], whereas a
recent Dutch study identiﬁed an underlying risk factor in
14% [15].
Because conjugate vaccine failure is rare, case series
have often been too small for robust conclusions. In 1996, an
international collaboration was initiated to describe the impact
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of routine Hib immunization on the epidemiology of invasive
Haemophilus inﬂuenzae disease by pooling surveillance data
from Europe, Israel and Australia. The objective of the present
study was to describe the clinical and laboratory features of
children with Hib vaccine failure in a large and diverse
population with different immunization schedules and to
provide recommendations for the management of such cases.
Materials and Methods
The European Union Invasive Bacterial Infections Surveillance
(EU-IBIS) study (formerly known as BIOMED II) was estab-
lished in 1996 to describe the epidemiology of H. inﬂuenzae
disease and the impact of mass Hib vaccination on the epide-
miology of H. inﬂuenzae. Detailed descriptions of the surveil-
lance systems in place for the different countries are
available at http://www.euibis.org. Brieﬂy, the national refer-
ence centres received isolates and clinical samples from cases
and voluntary reports of invasive H. inﬂuenzae infections
from clinicians, microbiologists and public health doctors. All
countries had reference laboratories that routinely serotyped
H. inﬂuenzae, with only minor differences in the identiﬁcation
methods used. Invasive Hib disease was deﬁned as isolation
of H. inﬂuenzae serotype b from a normally sterile site in any
child <15 years. For each case, surveillance coordinators
were asked to contact clinicians to obtain information on
birth weight, gestation, dates and type of vaccine adminis-
tered and any underlying medical problems. A case was des-
ignated as true vaccine failure (TVF) if invasive Hib disease
occurred ‡2 weeks after one Hib vaccine dose, given after
the ﬁrst birthday, or ‡1 week after ‡2 doses, given at
<1 year of age. For immunological studies, acute and conva-
lescent serum specimens were obtained within 48 h and at
least 10 days after hospital admission, respectively. Hib anti-
body concentrations were measured using ELISA as part of
routine clinical investigation in individual centres in participat-
ing countries. The ELISA method has been shown to yield
reproducible results both within and between laboratories
[16,17], even when clinical samples are re-tested after
several years [18]. Immunoglobulin deﬁciency was deﬁned as
IgG, IgA and/or IgM concentrations >2 standard deviations
below the mean for age [19]. A full-time data ofﬁcer was
responsible for the day-to-day running of the study and data
entry. Any missing, inconsistent or conﬂicting data were
resolved with the lead investigator for that country and
corrected in the database. For the present study, data were
downloaded into Microsoft Excel (Microsoft Corp., Red-
mond, WA, USA) and statistical analysis was performed using
Stata 8.0 software (StataCorp, College Station, TX, USA).
Signiﬁcance tests for trends in proportions were determined
using Epi Info, version 6 (http://www.cdc.gov). Continuous
variables following a normal distribution were compared
using Student’s t-test. Otherwise, data were described as
median and interquartile ranges (IQR) and compared using
the Mann–Whitney U-test. Proportions were compared using
the chi-square test or Fisher’s exact test, as appropriate. The
risk of Hib vaccine failure was calculated by dividing the total
number of TVF cases in each country by mid-year population
estimates for children <15 years in that country for the
years of participation in the EU-IBIS study. Risk factors for
low convalescent Hib antibody concentrations were assessed
using backward stepwise logistic regression. Ethical approval
was not sought because all data were collected as part of
national surveillance, subject to local public health legislation.
All investigations, including blood tests, were performed at
the clinician’s discretion as part of routine clinical care.
Results
The type of Hib vaccine used varied considerably among
countries and, often, several different vaccines were used
and changed during the study period. However, the Hib
tetanus toxoid conjugate, PRP-T, predominated in most
countries. Twelve countries reported 491 children with
TABLE 1. Vaccination schedules and risk of Hib vaccine failure
(per 100 000 child years at risk) in participating countries
Country Vaccine schedule (months)
All Hib
vaccine
failure
cases
(n = 491)
True
vaccine
failure
cases
(n = 423)
Australia 2, 4, 6, 18 months (1996–2000)
2, 4, 12 months (2001)
0.37 (86) 0.28 (66)
Denmarka 5, 6, 15 months (1996)
3, 5, 12 months (1997–2001)
0.07 (2) 0.03 (1)
Finland 4, 6, 14–18 months 0.11 (6) 0.09 (5)
Germany 2, 3, 4, 11–14 months 0.07 (37) 0.06 (31)
Ireland 2, 4, 6 months 0.41 (22) 0.32 (17)
Israel 2, 4, 12 months (1996–June 1997)
2, 4, 6, 12 months (July 1997
onwards)
0.20 (21) 0.15 (16)
Italyb 3, 5, 11–12 months if <12 months old
1 dose if >12 months old
0.03 (6) 0.00 (1)
Netherlands 3, 4, 5, 11 months 0.17 (29) 0.12 (21)
Norway 3, 5, 11–12 months (2001 onwards) 0.04 (1) 0.04 (1)
Spainc 2, 4, 6, 15–18 months if <12 months
old
1 dose if >12 months old
0.16 (5) 0.13 (4)
Sweden 3, 5, 12 months 0.07 (7) 0.06 (6)
UK 2, 3, 4 months if <6 months old
1 dose if 12–48 months old
0.45 (269) 0.43 (254)
The total number of cases is indicated in parenthesis.
aDenmark: surveillance involved meningitis cases only.
bItaly: surveillance performed in eight of 20 regions only.
cSpain: Valencia and Basque Regions only.
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invasive Hib disease who had received at least one dose of
Hib vaccine (Table 1), including 423 (86%) who fulﬁlled the
TVF deﬁnition criteria, 61 who developed disease too early
after vaccination, and seven cases in which the vaccination
history was unknown.
All TVF cases
The overall rate of TVF was 0.20 per 100 000 child-years.
Of the 423 TVF cases, 330 had received three doses before
12 months of age, 48 had received two doses before
12 months, 34 had received three doses before 12 months
with a booster dose in the second year, and 11 had received
one dose of Hib conjugate vaccine after the age of
12 months. The median age at the time of Hib disease was
27.2 months (IQR 15.8–41.2 months) and 59% were male.
Children <5 years accounted for 378 (89%) cases, with 184
(43%) cases occurring in <2 year-olds. The most common
clinical presentation was meningitis (185 cases, 44%; median
age, 23.3 months; IQR 14.0–36.8 months), followed by
bacteraemia (83 cases, 20%; median age, 28.8 months; IQR
14.6–47.1 months) and epiglottitis (64 cases, 15%; median
age, 36.9 months; IQR 24.5–46.1 months). The clinical
presentation was similar among the different groups (Table 2),
but varied with age (Fig. 1). Almost 60% (41/70 cases, 59%)
of infants (age <1 year) presented with meningitis compared
to 42% (128/308 cases) of 1–4 year-olds and 36% (16/45
cases) of 5–14 year-olds (v2 for trend = 7.0, p 0.008),
whereas epiglottitis was rare in infants (one case, 1%).
Of the 254 UK cases, information on underlying medical
problems was available for 220 cases (87%) and was present
in 35 (16%) children (Table 3). Fourteen children were born
before 37 weeks of gestation, with nine being born before
34 weeks. The median age at time of infection was similar in
premature (22 months; IQR 14–33 months) and term births
(29 months; IQR 17–41 months; p 0.21). Serum immuno-
TABLE 2. A comparison of clinical presentation, risk factors and outcome among different vaccination schedules
Vaccination schedule
TVF-3 (TVF
after 3 doses,
n = 330)
TVF-2 (TVF
after 2 doses,
n = 48)
TVF-B (TVF
after 4 doses,
including booster,
n = 34)
TVF-1 (TVF after
1 dose given after
12 months of age
(n = 11)
ALL TVF
cases (n = 423)
Clinical presentation: number of cases (%)
Meningitis 147 (44.5) 22 (45.8) 13 (38.2) 3 (27.3) 185 (43.7)
Epiglottitis 56 (17.0) 3 (6.3) 3 (8.8) 2 (18.2) 64 (15.1)
Bacteraemia 57 (17.3) 12 (25.0) 11 (32.4) 3 (27.3) 83 (19.6)
Other 68 (20.6) 10 (20.8) 7 (20.6) 3 (27.3) 88 (20.8)
Not reported 2 (0.6) 1 (2.1) 0 (0.0) 0 (0.0) 3 (0.7)
Underlying medical problems: number of
children/total cases (%)
Underlying medical problem 37/231 (16%) 5/14 (36%) 1/5 (20%) 4/6 (67%) 47/258 (18%)
Immunologlobulin deﬁciency 50/154 (32%) 1/5 (20%) 0/0 2/2 (100%) 53/161 (33%)
One or both conditions in children who had
information on both available
59/141 (42%) 2/5 (40%) 0/0 2/2 (100%) 63/148 (43%)
Convalescent Hib antibody concentrations <1 mg/L 44/184 (24%) 2/4 (50%) 0/3 1/3 (33%) 47/194 (24%)
Median age (months) at vaccination/disease (IQR)
First dose of vaccine 2.0 (1.9–2.3) 2.5 (2.0–3.7) 2.9 (2.0–3.6) – –
Second dose of vaccine 3.3 (3.0–3.9) 4.9 (3.9–6.2) 4.3 (4.1–5.1) – –
Third dose of vaccine 4.7 (4.0–6.0) – 6.3 (5.7–7.2) – –
Booster dose of vaccine – – 14.6 (12.4–18.4) 32.9 (21.9–38.7) –
Median time to Hib diseasea 21.0 (9.6–33.6) 5.9 (1.3–13.3) 11.4 (0.3–19.6) 33.7 (32.5–37.5) –
Median age at Hib disease 28.4 (16.3–41.1) 11.7 (6.8–20.9) 32.7 (24.2–42.4) 71.1 (52.3–74.0) 27.2 (15.8–41.2)
Children developing Hib disease within 12 months
of last vaccine dose
55 (17%) 31 (65%) 10 (29%) 1 (9%) 97 (23%)
Case fatality ratio, number (%) 8 (2.4%) 1 (2.1%) 1 (2.9%) 0 (0.0%) 10 (2.4%)
Median age at death (months) 17.2 16.5b 22.3b – 17.2
IQR, interquartile range; TVF, true vaccine failure.
aAfter last dose of vaccine.
bOnly one child died in this group.
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FIG. 1. Clinical presentation of children with Hib vaccine failure
(n = 423) in different age groups.
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globulin concentrations were measured in 146 UK children
and 45 (31%) had immunoglobulin deﬁciency. The presence
of immunoglobulin deﬁciency was not associated with earlier
onset of disease [median 31 months (IQR 19–37 months) vs.
33 months (IQR 20–43 months); p 0.48]. When considered
together, 53 out of 133 (40%) of UK children with TVF for
whom all information was available had either an underlying
medical problem or immunoglobulin deﬁciency. For countries
other than the UK, underlying medical problems and
immunoglobulin deﬁciency were reported for only 38 (22%)
and 15 (9%) of 169 cases, but were present in a higher pro-
portion of children [12 cases (32%) and eight cases (53%),
respectively].
Acute sera were taken from 34 children and 15 (44%) had
Hib antibody concentrations <0.15 mg/L, whereas 28 (82%)
had concentrations <1 mg/L. Convalescent antibody concen-
trations measured at a median of 36 days after diagnosis
(IQR 19–55 days) were available for 194 children. Most chil-
dren (180/194, 93%) had concentrations ‡0.15 mg/L,
whereas 147 (76%) had concentrations ‡1.0 mg/L (Table 2).
In a univariate analysis, low convalescent antibody concentra-
tions (<1.0 mg/L) were associated with young age at the time
of disease [median age at disease onset, 18 months
(IQR 11–29 months) vs. 34 months (IQR 23–44 months);
p <0.0001] and underlying medical problems (excluding
prematurity) [7/47 (15%) vs. 8/147 (5%); v2 = 4.5, p 0.035],
but not with prematurity [5/42 (12%) vs. 8/126 (6%);
v2 = 1.4, p 0.24] or immunoglobulin deﬁciency [14/33 (42%)
vs. 33/109 (30%); v2 = 1.7, p 0.19]. In a logistic regression
model, the same risk factors (age <18 months onset: OR
5.8; 95% CI 2.8–12.2; p <0.0001) and underlying medical
problems excluding prematurity (OR 4.0; 95% CI 1.3–12.6;
p 0.02), but not clinical presentation, prematurity, presence
of immunoglobulin deﬁciency, interval between last vaccine
dose and onset of disease, or day at which convalescent
serum was collected, remained independently associated with
low convalescent antibody concentrations.
Twelve children with convalescent Hib antibody concen-
trations <1.0 mg/L received an Hib vaccine booster and, in
eleven, the resulting antibody concentration was >1.0 mg/L.
Ten children (10/423 cases, 2.4%; 95% CI 1.1–4.3%) died,
including four with meningitis (4/185 cases, 2.2%) and two
each with epiglottitis (2/64 cases, 3.1%) and bacteraemia (2/
83 cases, 2.4%). Children who died were younger [median
17 months (IQR 15–22) months vs. 27 months (IQR
16–42 months); p 0.05], but were not more likely to have an
underlying medical problem or immunoglobulin deﬁciency.
TVF-3 cases (vaccine failure after three doses of Hib vaccine,
n = 330). All countries reported vaccine failure cases after
three doses (TVF-3), with the UK reporting the most (242/
330, 73%). The majority of children in this group (83%) pre-
sented at least 12 months after the last dose of vaccine.
There was insufﬁcient clinical and laboratory information
for children (n = 38) who received a late third dose at
11–18 months of age (as recommended in many Scandinavian
countries) to consider this group separately from children
who received three early doses of vaccine. Exclusion of
these children from the analysis did not substantially change
the proportion of children with underlying medical problems
or immunoglobulin deﬁciency, or those with low convales-
cent Hib antibody concentrations.
TVF-2 (vaccine failure after two doses of Hib vaccine,
n = 48). This group had the shortest interval between the last
dose of vaccine and onset of disease [median 5.9 months (IQR
1.3–13.3 months) vs. 20.7 months (IQR 9.3–33.2 months);
p <0.0001]. Most cases occurred in Australia (18 cases, 38%),
Germany (11 cases, 23%), and the UK (nine cases, 19%).
Within this group, 73% of children would have received the
third dose before the onset of disease if national immunization
schedules in the respective countries had been followed.
TVF-B (vaccine failure after three doses in the ﬁrst 6 months and
a second year booster, n = 34). Most cases occurred in Aus-
tralia (11 cases, 32%), the Netherlands (six cases, 18%) and
Germany (six cases 18%). Convalescent Hib antibody con-
centrations measured in three children were all >1 mg/L.
TVF-1 (vaccine failure after one dose >12 months of age,
n = 11). Australia (ﬁve cases, 45%) and the UK (three cases,
27%) reported 8/11 cases. The median age at the time of
Hib disease [71 months (IQR 52–74 months) vs. 27 months
(IQR 15–41 months); p <0.0001] and the time interval
between vaccination and onset of disease [34 months (IQR
TABLE 3. Underlying medical problems in 258 of 423 chil-
dren with true vaccine failure for whom the information
was available
Underlying medical problems
UK cases
(n = 220)
(%)
Other
countries
(n = 38) (%)
All cases
(n = 258)
(%)
Prematurity (gestation <37 weeks) 14 (6) 7 (18) 21 (8)
Malignancy 9 (4) 2 (5) 11 (4)
Dysmorphic 4 (2) 2 (5) 6 (2)
Down’s syndrome 2 (1) 0 (0) 2 (1)
Other chromosomal abnormality 2 (1) 0 (0) 2 (1)
Other 7 (3) 3 (8) 10 (4)
Total 35 (16)a 12 (32)b 47 (18)c
aThree UK children had more than one risk factor.
bTwo children from other countries had more than one risk factor.
cFive children had more than one risk factor.
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32–37 months) vs. 18 months (IQR 7–32 months);
p <0.0001] were signiﬁcantly greater than in other TVF cases
(Table 2). Five of six children (83%) in this group had an
underlying medical problem or immunoglobulin deﬁciency.
Discussion
In countries with established Hib vaccination programmes,
the development of invasive Hib disease after prior immuni-
zation is extremely rare. However, Hib vaccine failure
can occur at any age and with any vaccination schedule. Com-
pared to children with invasive Hib disease in the pre-vaccine
era, Hib vaccine failure cases presented at an older age, were
less likely to develop meningitis (44% vs. 65–75%) and more
likely to have bacteraemia (20% vs. <5%) [20–25], but overall
case fatality was similar [21,23,26–28]. The lower risk of men-
ingitis is largely explained by the older age of vaccine failure
cases because meningitis is a particular feature of cases pre-
senting in infancy. However, it is also possible that prior Hib
vaccination may reduce meningeal invasion by reducing the
duration/intensity of bacteraemia [12,15,23,29]. The propor-
tion of vaccine failure cases presenting with epiglottitis was
similar to that among Western European [21,23,26–28] and
non-Aboriginal Australian populations [27,30] in the pre-vac-
cine era. Epiglottitis is rare in populations with a very high
incidence of Hib disease, where disease occurs at a very
young age [27]. It is not clear whether such populations are
genetically less susceptible to epiglottitis or whether, like
meningitis, this reﬂects age-speciﬁc susceptibility because epi-
glottitis is mainly an infection of older children.
Hib antibody concentrations in the acute phase of illness
are not measured routinely. However, in the 34 children
where they were measured, most had low or undetectable
antibody concentrations. This ﬁnding is consistent with previ-
ous studies [12,14,15] and suggests an impaired primary
response to vaccination or failure to maintain protective
antibody concentrations. Convalescent Hib antibody concen-
trations were measured more frequently because they help
determine whether the child requires a booster dose of vac-
cine after infection. The ﬁnding that one quarter of children
did not develop long-term protective antibody concentra-
tions after infection suggests that they may be susceptible to
further episodes of Hib disease, although such episodes are
rare [31]. The proportion of Hib vaccine failure cases with
protective antibody response after infection, however, is
higher than that of unvaccinated children in the pre-vaccine
era [32], suggesting that many were immunologically primed
by previous vaccination. This agrees with recent ﬁndings in
children with meningococcal C conjugate vaccine failure [33].
Young age at the time of Hib disease and underlying medi-
cal problems were associated with low convalescent anti-
body concentrations after infection. These associations are
biologically plausible because young infants are less able to
respond to polysaccharide antigens of encapsulated bacteria
[34] and underlying medical conditions such as malignancy,
immunosuppression and Down’s syndrome are often associ-
ated with poor immune responses to vaccines [35–38].
Finally, immunoglobulin deﬁciency is a recurrent ﬁnding in
children with Hib vaccine failure [12–15]. This ﬁnding may be
speciﬁc to Hib because a recent case–control study of
meningococcal serogroup C vaccine failure found lower pro-
portions of children with immunoglobulin deﬁciency among
both vaccinated (13%) and unvaccinated (19%) children [33].
Without equivalent data for unvaccinated controls, it is not
possible to determine whether these conditions are genuine
risk factors for Hib vaccine failure. The rate of prematurity
among UK cases, for example, is similar to the national back-
ground rate of 7.4%, although the proportion of children
born <34 weeks (4%) is higher than the 1.3% [39], suggesting
that the extent of prematurity may be an important risk
factor.
Despite the large number of cases, the present study has
several limitations that prevent the reliable determination of
vaccine failure rates by vaccine or schedule. The quality of
surveillance varied among countries and may have affected
the completeness of ascertainment. Data on age-speciﬁc
vaccine coverage in all cohorts eligible for vaccine (including
catch-up campaigns, private practice and sub-national
programmes) were limited and we could not adjust for
changes in vaccine combinations used or for adherence to
recommended schedules. Because vaccine coverage in most
countries was high, however, the higher vaccine failure rates
observed in the UK and Ireland do suggest that a booster
dose may have an important role in reducing the risk of
vaccine failure. Because most children with vaccine failure
who received three doses before 6 months of age developed
disease at least 1 year after their last dose of vaccine, the
recent implementation of a booster dose at 13 months of
age in the UK and Ireland should reduce the future burden
of Hib disease in these countries [40,41].
We conclude that children with Hib vaccine failure should
be evaluated for immunoglobulin deﬁciency and have convales-
cent Hib antibody concentrations measured after infection,
particularly if they develop disease at a young age (i.e. before
18 months) or if they have an underlying medical problem.
Children with convalescent antibody concentrations <1 mg/L
(or when it has not been possible to measure antibody
responses) should receive an additional dose of Hib conjugate
vaccine as soon as possible, aiming to achieve antibody
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concentrations consistent with long- term protection against
invasive Hib disease.
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